Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
暂无分享,去创建一个
Reto Meuli | Serge Leyvraz | Alessia Pica | Raymond Miralbell | Ivan Maillard | Luca Regli | R. Meuli | R. Mirimanoff | R. Stupp | R. Janzer | A. Pica | R. Miralbell | S. Leyvraz | N. de Tribolet | L. Regli | F. Porchet | I. Maillard | P. Dietrich | Roger Stupp | Pierre-Yves Dietrich | Sandrine Ostermann Kraljevic | Phillipe Maeder | Robert Janzer | Gianpaolo Pizzolato | François Porchet | Nicolas de Tribolet | René O Mirimanoff | G. Pizzolato | P. Maeder | Sandrine Ostermann Kraljevic
[1] W. Curran,et al. Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] H. Fine,et al. Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.
[3] D. Osoba,et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.
[4] E. Newlands,et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). , 1992, British Journal of Cancer.
[5] J. Buckner,et al. Chemotherapy for high-grade gliomas , 2000, British Journal of Cancer.
[6] S. Green,et al. Glioblastoma multiforme and anaplastic astrocytoma pathologic criteria and prognostic implications , 1985, Cancer.
[7] R. McLendon,et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] E S Newlands,et al. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. , 1997, Cancer treatment reviews.
[9] S. Piantadosi,et al. The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma. , 1999, International journal of radiation oncology, biology, physics.
[10] D. Nelson,et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.
[11] B. Scheithauer,et al. The New WHO Classification of Brain Tumours , 1993, Brain pathology.
[12] E. Newlands,et al. In vitro evaluation of temozolomide combined with X-irradiation , 1997, Anti-cancer drugs.
[13] M Brada,et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] R. Stupp,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Review Temozolomide for Brain Tumours Current and Future Developments in the Use of Temozolomide for the Treatment of Brain Tumours , 2022 .
[15] M. Roddie,et al. Phase I trial of temozolomide using an extended continuous oral schedule. , 1998, Cancer research.
[16] Susan M. Chang,et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] S. Piantadosi,et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas , 1995, The Lancet.
[18] H. Friedman,et al. Temozolomide and treatment of malignant glioma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] R. Hatlevoll,et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the scandinavian glioblastoma study group , 1981, Cancer.
[20] M. member. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a medical research council trial. , 2001 .
[21] D P Byar,et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.
[22] W. Curran,et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. , 1998, International journal of radiation oncology, biology, physics.
[23] J. Heimans,et al. Survival of human glioma cells treated with various combination of temozolomide and X-rays. , 2000, International journal of radiation oncology, biology, physics.
[24] E. Alexander,et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.
[25] J. Reid,et al. Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] M. Berger,et al. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. , 2001, Cancer research.
[27] T. Buclin,et al. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration , 1998, Cancer Chemotherapy and Pharmacology.